Last edition
News about "Royalty Pharma "
Royalty Pharma Signs R&D Funding Agreement with Biogen
Litifilimab is currently in Phase 3 trials for both SLE and CLE with results expected between 2026 and 2027.
Royalty Pharma | 13/02/2025 | By Aishwarya
Syndax Signs USD 350 Million Royalty Funding Deal with Royalty Pharma for Niktimvo
Under the terms of the agreement, Syndax received an upfront payment of USD 350 million in exchange for a 13.8 percent royalty on US net sales of Niktimvo.
Royalty Pharma | 06/11/2024 | By Aishwarya | 107
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy